US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ABVC BioPharma, Inc.

0.8550

-0.1150-11.86%

Post-market: 0.86600.0110+1.29%19:13 EDT

Volume:226.52K

Turnover:203.01K

Market Cap:13.49M

PE:-2.04

High:0.9900

Open:0.9900

Low:0.8500

Close:0.9700

Loading ...

Overview Company News Filings

UPDATE: ABVC BioPharma Announces 2024 Financial Results

ABVC BioPharma Determined That It Has A Material Weakness In Its Internal Controls Over Financial Reporting; Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements

ABVC Biopharma Inc: Determined That It Has a Material Weakness in Its Internal Controls Over Financial Reporting

THOMSON REUTERS

ABVC Biopharma : Concluded That Financial Statements for FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due to Errors in Financial Statements

THOMSON REUTERS

Johnson & Johnson says ‘continues to be excited’ about icotrokinra potential

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Hefei Lifeon Pharmaceutical Gets Drug Registration for ADHD Tablets; Shares Soar 10%

MT Newswires Live

ABVC's Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 Million

Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301

Neumora Therapeutics, Inc. Faces Setbacks with Delayed MDD Program and Discontinued Bipolar Depression Study

Why Shares of Axsome Therapeutics Slumped Today

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression

Press Release: Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Buy Rating Affirmed for Axsome Therapeutics Amid Promising ADHD Treatment Results and Strategic Market Positioning

Axsome Therapeutics' Phase 3 Trial of Solriamfetol to Treat ADHD Meets Primary Endpoint

MT Newswires Live

Press Release: Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

We Are Turning Too Many People into Medical Patients -- WSJ

Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ABVC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ABVC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABVC\",,,,,undefined,":{"symbol":"ABVC","market":"US","secType":"STK","nameCN":"ABVC BioPharma, Inc.","latestPrice":0.855,"timestamp":1744920000000,"preClose":0.97,"halted":0,"volume":226517,"hourTrading":{"tag":"盘后","latestPrice":0.866,"preClose":0.855,"latestTime":"19:13 EDT","volume":1349,"amount":1154.0185,"timestamp":1744931624664},"delay":0,"floatShares":12929900,"shares":15778300,"eps":-0.42,"marketStatus":"Market Closed","change":-0.115,"latestTime":"04-17 16:00:00 EDT","open":0.99,"high":0.99,"low":0.85,"amount":203010.20738568,"amplitude":0.14433,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.42,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1627963200000,"exchange":"NASDAQ","adjPreClose":0.97,"preHourTrading":{"tag":"盘前","latestPrice":0.965,"preClose":0.97,"latestTime":"09:11 EDT","volume":1142,"amount":1142.1899146,"timestamp":1744895496229},"postHourTrading":{"tag":"盘后","latestPrice":0.866,"preClose":0.855,"latestTime":"19:13 EDT","volume":1349,"amount":1154.0185,"timestamp":1744931624664},"volumeRatio":0.7186028992688421},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABVC\",,,,,undefined,":{"symbol":"ABVC","floatShares":12929900,"roa":"-38.38%","roe":"-531.91%","lyrEps":-0.419983,"volumeRatio":0.7186028992688421,"shares":15778300,"dividePrice":0,"high":0.99,"amplitude":0.14433,"preClose":0.97,"low":0.85,"week52Low":0.4,"pbRate":"11.00","psRate":"26.47","week52High":1.73,"institutionHeld":0,"latestPrice":0.855,"eps":-0.42,"divideRate":0,"volume":226517,"delay":0,"ttmEps":-0.42,"open":0.99,"prevYearClose":0.59,"prevWeekClose":0.914,"prevMonthClose":1.06,"prevQuarterClose":1.06,"fiveDayClose":1.05,"twentyDayClose":0.665,"sixtyDayClose":0.52},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ABVC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527621023","title":"UPDATE: ABVC BioPharma Announces 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2527621023","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527621023?lang=en_us&edition=fundamental","pubTime":"2025-04-16 21:00","pubTimestamp":1744808400,"startTime":"0","endTime":"0","summary":"Revenue Surges 234%, Expenses Down 21%, EPS Improves 77%, with Over $18.3 Million Licensing Incomes Available. Revenue Growth of 234% Fueled by Global Licensing Milestones. ABVC reported total revenues of $509,589 in 2024, representing a 234% increase compared to $152,430 in 2023. This significant growth was primarily driven by milestone payments collected from the Company's global licensing partners in CNS, oncology, and ophthalmology therapeutic areas.Importantly, ABVC remains eligible to receive up to an additional $18.3 million in milestone payments under existing licensing agreements, which, if received, will provide strong non-dilutive funding visibility to support future growth.Operating Expenses Reduced by 21% Reflecting Cost Discipline. Total operating expenses were reduced to $5.21 million in 2024, down 21% from $6.62 million in 2023. The decline was primarily driven by:. Selling, General and Administrative expenses reduced by 58%. \"2024 was a breakthrough year for ABVC. We d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abvc-biopharma-announces-2024-financial-130000454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4022","BK4232","ABVC","BK4139","R"],"gpt_icon":0},{"id":"2527747836","title":"ABVC BioPharma Determined That It Has A Material Weakness In Its Internal Controls Over Financial Reporting; Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements","url":"https://stock-news.laohu8.com/highlight/detail?id=2527747836","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527747836?lang=en_us&edition=fundamental","pubTime":"2025-04-16 04:43","pubTimestamp":1744749806,"startTime":"0","endTime":"0","summary":"- SEC Filing","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44826993/abvc-biopharma-determined-that-it-has-a-material-weakness-in-its-internal-controls-over-financial-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"gpt_icon":0},{"id":"2527201614","title":"ABVC Biopharma Inc: Determined That It Has a Material Weakness in Its Internal Controls Over Financial Reporting","url":"https://stock-news.laohu8.com/highlight/detail?id=2527201614","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527201614?lang=en_us&edition=fundamental","pubTime":"2025-04-16 04:35","pubTimestamp":1744749313,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT15H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABVC","BK4139"],"gpt_icon":0},{"id":"2527201014","title":"ABVC Biopharma : Concluded That Financial Statements for FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due to Errors in Financial Statements","url":"https://stock-news.laohu8.com/highlight/detail?id=2527201014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527201014?lang=en_us&edition=fundamental","pubTime":"2025-04-16 04:35","pubTimestamp":1744749313,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT15H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABVC"],"gpt_icon":0},{"id":"2527533419","title":"Johnson & Johnson says ‘continues to be excited’ about icotrokinra potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2527533419","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527533419?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:50","pubTimestamp":1744721412,"startTime":"0","endTime":"0","summary":"Says anticipates potential approval for CAPLYTA as adjunctive treatment for MDD later this year. Says plans to file for icotrokinra approval later ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/johnson-johnson-says-continues-to-be-excited-about-icotrokinra-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/johnson-johnson-says-continues-to-be-excited-about-icotrokinra-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JNJ","IE0034235303.USD","LU2505996509.AUD","LU0795875169.SGD","LU1929549753.HKD","LU2089984988.USD","LU2430703095.HKD","LU1506573853.SGD","IE00B3PB1722.GBP","LU0795875086.SGD","LU1162221912.USD","LU1674673691.USD","IE00B1BXHZ80.USD","BK4139","LU0912757837.SGD","IE00B19Z3581.USD","IE00BJT1NW94.SGD","LU1196500208.SGD","LU1066051225.USD","LU0058720904.USD","LU0889566641.SGD","LU1267930813.SGD","IE00BDGV0183.EUR","LU0203347892.USD","IE00BSNM7G36.USD","LU1261432733.SGD","IE00BN8TJ469.HKD","ABVC","LU1032955483.USD","LU1430594728.SGD","BK4585","LU1221951046.USD","IE0002270589.USD","IE0002141913.USD","BK4533","LU1280957306.USD","IE00BFTCPJ56.SGD","LU1914381329.SGD","LU1778281490.HKD","BK4592","LU0114720955.EUR","LU1066053197.SGD","IE00B4R5TH58.HKD","LU0320765646.SGD","LU1935042991.SGD","LU1244550577.SGD","LU2129689514.USD","LU0203345920.USD","BK4550","LU0640476718.USD"],"gpt_icon":0},{"id":"2527541636","title":"MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527541636","media":"Business Wire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527541636?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"- Emerge is the first Phase 3 study of lysergide D-tartrate  in MDD; primary endpoint will measure change from baseline in Montgomery-sberg Depression Rating Scale  score at Week 6 between MM120 Orally Disintegrating Tablet  100 g and placebo -. - Topline data from the 12-week double-blind period anticipated in the second half of 2026 -. \"In our Phase 2b study, MADRS score improvements after a single MM120 100 g dose were clinically and statistically significant compared to placebo, providing meaningful benefits to participants. Having dosed the first participant in the Phase 3 Emerge study, we are excited for the therapeutic potential that MM120 ODT shows for the 21 million people in the U.S. affected by MDD,\" said Daniel R. Karlin, M.D., M.A., Chief Medical Officer of MindMed. \"By running our MDD and GAD Phase 3 studies concurrently, we can leverage the shared symptomatology between these conditions to more effectively match participants to the appropriate study based on their clinic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-announces-first-patient-dosed-110000855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ODT","BK4547","BK4139","BK4007","MNMD","ABVC"],"gpt_icon":0},{"id":"2527843036","title":"Hefei Lifeon Pharmaceutical Gets Drug Registration for ADHD Tablets; Shares Soar 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527843036","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527843036?lang=en_us&edition=fundamental","pubTime":"2025-04-15 14:35","pubTimestamp":1744698915,"startTime":"0","endTime":"0","summary":"Hefei Lifeon Pharmaceutical  obtained drug registration from China's drug administrator for its methylphenidate hydrochloride extended-release tablets.The drug is a first-class psychotropic substance mainly used to treat attention deficit hyperactivity disorder, according to a Tuesday filing with the Shenzhen bourse.Shares of the pharmaceutical company rose 10% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0250","ABVC","ADHD","BK4139","003020"],"gpt_icon":0},{"id":"2524693257","title":"ABVC's Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2524693257","media":"NewMediaWire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524693257?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:00","pubTimestamp":1743685200,"startTime":"0","endTime":"0","summary":"The acquired land will be designated for the cultivation and extraction of Polygala tenuifolia , a central ingredient in AiBtl's botanical drug candidates for Major Depressive Disorder  and Attention Deficit Hyperactivity Disorder . The Company believes this move is key to reducing sourcing risk and supporting large-scale, high-quality production of active botanical compounds.\"This agreement is a long-term investment into securing the future of botanical drug innovation,\" said Uttam Patil, Ph.D., Chief Executive Officer of ABVC. \"By locking in upstream resources in Asia, we are strengthening AiBtl's infrastructure from seed to formulation - giving our neuroscience pipeline a sustainable foundation.\". The transaction also reflects ABVC's continuing efforts to expand its physical and operational footprint in the Asia-Pacific region while enhancing value for global shareholders.ADHD Drug Candidate: The ADHD market is expected to exceed $24 billion by 2032, fueled by increasing diagnoses a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abvcs-subsidiary-aibtl-signs-share-130000720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4022","BK4232","ABVC","ADHD","USD","R","BK4139"],"gpt_icon":0},{"id":"2524184251","title":"Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2524184251","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524184251?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:00","pubTimestamp":1743681600,"startTime":"0","endTime":"0","summary":"“Our meeting with the FDA yesterday was very productive, and we remain on track for an NDA filing of CTx-1301 in mid-2025. We truly appreciate the FDA personnel who have been involved with the regulatory review of CTx-1301 to date. These interactions have been essential in helping us generate data to demonstrate the consistency and therapeutic benefit of our product. This important milestone is validation of our mission to bring to market the first, true, once-daily stimulant medication to treat ADHD over the entire active day,” said Cingulate Chairman and CEO Shane J Schaffer.About CTx-1301Cingulate’s lead candidate, CTx-1301, utilizes Cingulate’s proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD. Dexmethylphenidate is part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cingulate-completes-pre-nda-meeting-120000674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CING","CINGW","ADHD","ABVC","BK4007","BK4139"],"gpt_icon":0},{"id":"2524145174","title":"Neumora Therapeutics, Inc. Faces Setbacks with Delayed MDD Program and Discontinued Bipolar Depression Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2524145174","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524145174?lang=en_us&edition=fundamental","pubTime":"2025-04-02 17:05","pubTimestamp":1743584724,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc. (NMRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazee...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/neumora-therapeutics-inc-faces-setbacks-with-delayed-mdd-program-and-discontinued-bipolar-depression-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/neumora-therapeutics-inc-faces-setbacks-with-delayed-mdd-program-and-discontinued-bipolar-depression-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ABVC","BK4007","NMRA"],"gpt_icon":0},{"id":"2524314147","title":"Why Shares of Axsome Therapeutics Slumped Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2524314147","media":"Motley Fool","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524314147?lang=en_us&edition=fundamental","pubTime":"2025-04-02 01:23","pubTimestamp":1743528180,"startTime":"0","endTime":"0","summary":"A phase 3 trial didn't go according to plan.Management is pushing forward with another phase 3 on the back of some positive data in the trial.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/01/why-shares-of-axsome-therapeutics-slumped-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4585","AXSM","ABVC","BK4139","BK4505","BK4597","BK4007","BK4215","ESS","BK4588"],"gpt_icon":0},{"id":"2524619454","title":"Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524619454","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524619454?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505200,"startTime":"0","endTime":"0","summary":"Results support continued development in MDD with concomitant EDS; Phase 3 trial planned in 2025 Approximately 50 percent of MDD patients experience EDS1, highlighting high unmet need NEW YORK, April ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053170/33090/en/Axsome-Therapeutics-Announces-Topline-Results-of-PARADIGM-Phase-3-Proof-of-Concept-Trial-of-Solriamfetol-in-Major-Depressive-Disorder-MDD-with-and-without-Excessive-Daytime-Sleepin.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESS","CNS","BK4505","AXSM","BK4135","ABVC","ADHD","BK4588","BK4597","BK4139","PACI.U","BK4585","BK4215"],"gpt_icon":0},{"id":"2523949576","title":"Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2523949576","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523949576?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:31","pubTimestamp":1743424260,"startTime":"0","endTime":"0","summary":"Policy update increases access for millions covered by Evernorth Health ServicesMALVERN, Pa., March  31, 2025  (GLOBE NEWSWIRE) -- Neuronetics,Inc. (NASDAQ: STIM), a vertically integrated, commercial ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052299/0/en/Evernorth-Health-Services-a-Cigna-Company-Expands-NeuroStar-TMS-Coverage-for-Adolescents-Struggling-with-Depression.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","STIM","ABVC","BK4139"],"gpt_icon":0},{"id":"2522416355","title":"Press Release: Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2522416355","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522416355?lang=en_us&edition=fundamental","pubTime":"2025-03-27 05:00","pubTimestamp":1743022800,"startTime":"0","endTime":"0","summary":"Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved. In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025. $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission. \"The capital raised over the past year has allowed us to strengthen our balance sheet and complete all required clinical trials for NDA submission for CTx-1301. We look forward to meeting with the FDA next week, submitting our new drug application this summer, and, assuming approval by the FDA, bringing to market the first, true, once-daily stimulant medication to treat ADHD over the entire active day,\" said Cingulate Chairman and CEO Shane J Schaffer.and adolescent studies -- a fixed dose study and a dose optimization. treatment emergent adverse events and confirming that the safety profile. and pediatric safety data will be prepared and included i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4099","BK4555","BK4604","TM","BK4585","BK4588","BK4007","03160","ABVC","CING"],"gpt_icon":0},{"id":"2522845871","title":"Buy Rating Affirmed for Axsome Therapeutics Amid Promising ADHD Treatment Results and Strategic Market Positioning","url":"https://stock-news.laohu8.com/highlight/detail?id=2522845871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522845871?lang=en_us&edition=fundamental","pubTime":"2025-03-26 16:35","pubTimestamp":1742978128,"startTime":"0","endTime":"0","summary":"Analyst Jason Gerberry from Bank of America Securities maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) and increased the pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-axsome-therapeutics-amid-promising-adhd-treatment-results-and-strategic-market-positioning?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-axsome-therapeutics-amid-promising-adhd-treatment-results-and-strategic-market-positioning?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","AXSM","ADHD"],"gpt_icon":0},{"id":"2522021437","title":"Axsome Therapeutics' Phase 3 Trial of Solriamfetol to Treat ADHD Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2522021437","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522021437?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:45","pubTimestamp":1742903124,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics  said Tuesday that the phase 3 trial of solriamfetol as a potential treatment for attention deficit hyperactivity disorder achieved its primary and key secondary endpoints, demonstrating \"statistically significant\" improvement in symptoms and disease severity.The study met its primary endpoint of a statistically significant reduction in the Adult ADHD Investigator Symptom Rating Scale compared with placebo at week six. The study also achieved the key secondary endpoint of a significant reduction in overall ADHD disease severity, Axsome added.Solriamfetol was also well-tolerated in the study, with no serious adverse events reported, according to Axsome.Axsome Chief Executive Officer Herriot Tabuteau said the company plans to start a solriamfetol trial in pediatric patients this year.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4505","BK4585","ADHD","ABVC","AXSM","BK4007"],"gpt_icon":0},{"id":"2521499351","title":"Press Release: Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2521499351","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521499351?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:10","pubTimestamp":1742501400,"startTime":"0","endTime":"0","summary":"-- Favorable outcome from interim analysis of ongoing ALTO-300 Phase 2b MDD trial; topline results expected in mid-2026 --. -- Completed enrollment in ALTO-203 Phase 2 proof-of-concept MDD trial; on track to report topline data in the second quarter of 2025 --. -- Novel transdermal formulation of ALTO-101 demonstrated greater drug exposure and improved tolerability profile; topline data from Phase 2 trial of ALTO-101 in schizophrenia expected in the second half of 2025 --. -- Company's precision psychiatry approach underpins recently granted patents covering the use of ALTO-100 and ALTO-300 in biomarker defined populations --. -- Strong cash position of approximately $169 million expected to fund planned operations into 2028, and through at least four upcoming clinical study readouts --. Alto Neuroscience, Inc.   a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the ful","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ANRO","ABVC"],"gpt_icon":0},{"id":"2520742445","title":"We Are Turning Too Many People into Medical Patients -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2520742445","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520742445?lang=en_us&edition=fundamental","pubTime":"2025-03-18 00:08","pubTimestamp":1742227680,"startTime":"0","endTime":"0","summary":"When I meet a patient with a complicated medical history, I often start by asking when they were last perfectly well. Darcie couldn't remember ever being truly well.Darcie is 20 years old. She was referred to me because she was having regular seizures, but her illness began long before. It began with headaches as a child, which a neurologist diagnosed as migraine when she was 13. By the time she reached my office, her referral letter included hypermobile Ehlers Danlos syndrome , anorexia, irritable bowel syndrome, postural orthostatic tachycardia syndrome , autism, ADHD, depression and anxiety. She had also started having seizures every day, which was why she was in my clinic.Darcie was clearly sick. She had barely been out of her own home for a year. Yet I came to believe that most of her symptoms, including her seizures and faints, were psychosomatic.Take Darcie's diagnosis of PoTS, a condition in which changes in posture provoke a fall in blood pressure that can cause fainting or di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"gpt_icon":0},{"id":"2519633827","title":"Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?","url":"https://stock-news.laohu8.com/highlight/detail?id=2519633827","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519633827?lang=en_us&edition=fundamental","pubTime":"2025-03-14 22:55","pubTimestamp":1741964100,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics’ AXSM Auvelity  was launched in the United States in 2022 for the treatment of major depressive disorder , making it the first approved drug in the company’s portfolio.Auvelity generated sales worth $291.4 million in 2024, reflecting an increase of 124% year over year in the United States. Sales of the drug are being driven by an increase in unit sales volume and the momentum is likely to continue in 2025.Axsome is also working to expand the label of Auvelity for the larger commercial opportunity in other central nervous system  disorders like Alzheimer’s disease  agitation and smoking cessation.The successful development and potential approval of Auvelity in additional indications will help the drug address a broader patient population and drive sales further.Axsome is evaluating Sunosi in separate phase III studies for treating attention deficit hyperactivity disorder , MDD, binge eating disorder and excessive sleepiness associated with shift work disorder.Top-lin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/auvelity-other-drugs-aid-axsms-145500596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0109394709.USD","IE00BN0W2T93.GBP","ACAD","ADHD","JAZZ","BK4585","BK4139","AXSM","CNS","LU2065169927.USD","BK4533","LU0320765992.SGD","IE00BN0W2W23.USD","LU2065170008.USD","ABVC","BK4007","IE00BN0W2V16.EUR","LU0823416689.USD","BK4532","LU0889565916.HKD","LU2065171402.SGD","BK4135","LU2065171311.SGD","BK4505"],"gpt_icon":0},{"id":"2518782331","title":"Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2518782331","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518782331?lang=en_us&edition=fundamental","pubTime":"2025-03-11 06:57","pubTimestamp":1741647420,"startTime":"0","endTime":"0","summary":"STOUGHTON, Mass., March  10, 2025  (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its differe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3040237/34897/en/Collegium-Announces-Poster-Presentations-at-the-2025-National-Association-of-Pediatric-Nurse-Practitioners-National-Conference-on-Pediatric-Health-Care.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4194","ABVC","DEA","CNS","BK4023","BK4585","BK4588","BK4223","HCP","NHLD","BK4139","ADHD","BK4135","CII"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":129,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ABVC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-15","symbol":"ABVC","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1744689600000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2024-11-14","symbol":"ABVC","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.02},{"market":"US","date":"2024-08-14","symbol":"ABVC","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"","actualEps":-0.09},{"market":"US","date":"2024-05-17","symbol":"ABVC","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715918400000,"reportTimeType":"post","actualEps":-0.4},{"date":"2024-03-14","symbol":"ABVC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1710403200000,"name":null,"time":"Pre-Market","dateTimestamp":1710388800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ABVC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ABVC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ABVC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ABVC","date":"2025-04-17","current":-2.422481,"percent":0.439578,"low":-22.659095,"twenty":-12.48183,"median":-1.616463,"eighty":-0.794876,"high":-0.260274,"avg":-5.711369,"sd":6.043186,"marketCap":11877127},"quantilePoints":[{"date":"2020-04-24","current":-9.704796,"twenty":-105.054712,"median":-70.569383,"eighty":-20.090004,"marketCap":61481027},{"date":"2020-05-01","current":-9.704796,"twenty":-104.984049,"median":-70.569383,"eighty":-20.005723,"marketCap":61481027},{"date":"2020-05-08","current":-9.098246,"twenty":-104.984049,"median":-70.569383,"eighty":-18.908189,"marketCap":57638463},{"date":"2020-05-15","current":-15.82702,"twenty":-104.984049,"median":-70.569383,"eighty":-18.428786,"marketCap":57638463},{"date":"2020-05-22","current":-15.82702,"twenty":-104.984049,"median":-70.569383,"eighty":-18.226085,"marketCap":57638463},{"date":"2020-05-29","current":-15.82702,"twenty":-104.984049,"median":-70.569383,"eighty":-18.156709,"marketCap":57638463},{"date":"2020-06-05","current":-15.299453,"twenty":-104.984049,"median":-70.569383,"eighty":-17.714565,"marketCap":55717180},{"date":"2020-06-12","current":-15.563236,"twenty":-104.984049,"median":-70.569383,"eighty":-16.871014,"marketCap":56677821},{"date":"2020-06-19","current":-15.563236,"twenty":-104.984049,"median":-70.569383,"eighty":-16.368319,"marketCap":56677821},{"date":"2020-06-26","current":-15.563236,"twenty":-104.984049,"median":-70.569383,"eighty":-15.82702,"marketCap":56677821},{"date":"2020-07-02","current":-14.066248,"twenty":-104.984049,"median":-70.569383,"eighty":-15.82702,"marketCap":57638463},{"date":"2020-07-10","current":-14.066248,"twenty":-104.984049,"median":-70.569383,"eighty":-15.82702,"marketCap":57638463},{"date":"2020-07-17","current":-15.472873,"twenty":-104.984049,"median":-70.569383,"eighty":-15.731773,"marketCap":63402309},{"date":"2020-07-24","current":-17.58281,"twenty":-104.984049,"median":-64.954263,"eighty":-15.762085,"marketCap":72048078},{"date":"2020-07-31","current":-18.52056,"twenty":-104.984049,"median":-64.198981,"eighty":-15.771827,"marketCap":75890642},{"date":"2020-08-07","current":-17.817247,"twenty":-104.984049,"median":-60.422571,"eighty":-15.816469,"marketCap":73008719},{"date":"2020-08-14","current":-14.118204,"twenty":-104.984049,"median":-58.912006,"eighty":-15.816469,"marketCap":76088142},{"date":"2020-08-21","current":-14.296916,"twenty":-104.984049,"median":-47.962314,"eighty":-15.601069,"marketCap":77051284},{"date":"2020-08-28","current":-12.867224,"twenty":-104.984049,"median":-47.962314,"eighty":-15.563236,"marketCap":69346155},{"date":"2020-09-04","current":-14.296916,"twenty":-104.984049,"median":-47.962314,"eighty":-15.563236,"marketCap":77051284},{"date":"2020-09-11","current":-14.118204,"twenty":-104.984049,"median":-47.962314,"eighty":-15.563236,"marketCap":76088142},{"date":"2020-09-18","current":-14.296916,"twenty":-104.984049,"median":-47.962314,"eighty":-15.563236,"marketCap":77051284},{"date":"2020-09-25","current":-14.118204,"twenty":-104.984049,"median":-47.962314,"eighty":-15.299453,"marketCap":76088142},{"date":"2020-10-02","current":-14.654339,"twenty":-104.984049,"median":-47.962314,"eighty":-14.943492,"marketCap":78977566},{"date":"2020-10-09","current":-14.887513,"twenty":-104.984049,"median":-47.962314,"eighty":-14.873601,"marketCap":80234224},{"date":"2020-10-16","current":-15.910707,"twenty":-104.984049,"median":-47.962314,"eighty":-14.887513,"marketCap":85748593},{"date":"2020-10-23","current":-15.522641,"twenty":-104.984049,"median":-47.962314,"eighty":-14.957404,"marketCap":83657164},{"date":"2020-10-30","current":-15.134575,"twenty":-104.984049,"median":-46.033619,"eighty":-15.082344,"marketCap":81565734},{"date":"2020-11-06","current":-15.199238,"twenty":-104.984049,"median":-46.033619,"eighty":-15.134575,"marketCap":81914224},{"date":"2020-11-13","current":-15.009247,"twenty":-104.984049,"median":-43.698955,"eighty":-14.957404,"marketCap":80890296},{"date":"2020-11-20","current":-13.64563,"twenty":-104.984049,"median":-39.895803,"eighty":-14.839343,"marketCap":82154224},{"date":"2020-11-27","current":-14.327911,"twenty":-104.984049,"median":-39.895803,"eighty":-14.654339,"marketCap":86261935},{"date":"2020-12-04","current":-14.498482,"twenty":-104.984049,"median":-39.895803,"eighty":-14.484769,"marketCap":87288863},{"date":"2020-12-11","current":-15.351334,"twenty":-104.984049,"median":-38.369814,"eighty":-14.475627,"marketCap":92423502},{"date":"2020-12-18","current":-17.057037,"twenty":-104.984049,"median":-37.594122,"eighty":-14.484769,"marketCap":102692780},{"date":"2020-12-24","current":-17.739319,"twenty":-104.984049,"median":-36.826895,"eighty":-14.498482,"marketCap":106800491},{"date":"2020-12-31","current":-17.398178,"twenty":-104.984049,"median":-36.826895,"eighty":-14.498482,"marketCap":104746635},{"date":"2021-01-08","current":-20.052297,"twenty":-104.984049,"median":-36.67345,"eighty":-14.549617,"marketCap":120725895},{"date":"2021-01-15","current":-21.65648,"twenty":-104.984049,"median":-34.580924,"eighty":-14.654339,"marketCap":130383966},{"date":"2021-01-22","current":-21.255434,"twenty":-104.984049,"median":-33.757987,"eighty":-14.654339,"marketCap":127969448},{"date":"2021-01-29","current":-20.052297,"twenty":-104.984049,"median":-33.757987,"eighty":-14.666109,"marketCap":120725895},{"date":"2021-02-05","current":-19.851774,"twenty":-104.984049,"median":-33.757987,"eighty":-14.751318,"marketCap":119518636},{"date":"2021-02-12","current":-19.450728,"twenty":-104.984049,"median":-32.897231,"eighty":-14.809783,"marketCap":117104118},{"date":"2021-02-19","current":-20.052297,"twenty":-104.984049,"median":-32.897231,"eighty":-14.839343,"marketCap":120725895},{"date":"2021-02-26","current":-17.646021,"twenty":-104.984049,"median":-32.530424,"eighty":-14.873601,"marketCap":106238787},{"date":"2021-03-05","current":-17.646021,"twenty":-104.984049,"median":-31.609752,"eighty":-14.887513,"marketCap":106238787},{"date":"2021-03-12","current":-18.047067,"twenty":-104.984049,"median":-30.689079,"eighty":-14.920184,"marketCap":108653305},{"date":"2021-03-19","current":-10.850476,"twenty":-104.984049,"median":-30.689079,"eighty":-14.839343,"marketCap":106238787},{"date":"2021-03-26","current":-10.973777,"twenty":-104.984049,"median":-30.437981,"eighty":-14.654339,"marketCap":107446046},{"date":"2021-04-01","current":-11.097077,"twenty":-104.984049,"median":-30.103498,"eighty":-14.498482,"marketCap":108653305},{"date":"2021-04-09","current":-10.850476,"twenty":-104.984049,"median":-30.103498,"eighty":-14.386997,"marketCap":106238787},{"date":"2021-04-16","current":-10.850476,"twenty":-104.984049,"median":-29.613533,"eighty":-14.327911,"marketCap":106238787},{"date":"2021-04-23","current":-11.097077,"twenty":-104.984049,"median":-28.765565,"eighty":-14.296916,"marketCap":108653305},{"date":"2021-04-30","current":-11.097077,"twenty":-104.984049,"median":-28.224507,"eighty":-14.296916,"marketCap":108653305},{"date":"2021-05-07","current":-11.46698,"twenty":-104.984049,"median":-28.224507,"eighty":-14.296916,"marketCap":112275082},{"date":"2021-05-14","current":-13.730013,"twenty":-104.984049,"median":-27.28369,"eighty":-14.296916,"marketCap":132798484},{"date":"2021-05-21","current":-13.730013,"twenty":-104.984049,"median":-26.65832,"eighty":-14.296916,"marketCap":132798484},{"date":"2021-05-28","current":-13.730013,"twenty":-103.326706,"median":-26.132665,"eighty":-14.118204,"marketCap":132798484},{"date":"2021-06-04","current":-13.355558,"twenty":-100.840692,"median":-25.838836,"eighty":-14.118204,"marketCap":129176707},{"date":"2021-06-11","current":-12.981103,"twenty":-100.840692,"median":-25.62158,"eighty":-14.066248,"marketCap":125554930},{"date":"2021-06-18","current":-11.857738,"twenty":-100.840692,"median":-25.489795,"eighty":-14.066248,"marketCap":114689600},{"date":"2021-06-25","current":-12.48183,"twenty":-100.840692,"median":-23.923098,"eighty":-13.947524,"marketCap":120725895},{"date":"2021-07-02","current":-11.233647,"twenty":-100.840692,"median":-23.282,"eighty":-13.770344,"marketCap":108653305},{"date":"2021-07-09","current":-12.48183,"twenty":-100.840692,"median":-22.944579,"eighty":-13.730013,"marketCap":120725895},{"date":"2021-07-16","current":-12.48183,"twenty":-100.840692,"median":-22.775869,"eighty":-13.730013,"marketCap":120725895},{"date":"2021-07-23","current":-12.357012,"twenty":-100.840692,"median":-22.633127,"eighty":-13.64563,"marketCap":119518636},{"date":"2021-07-30","current":-12.357585,"twenty":-100.840692,"median":-22.438449,"eighty":-13.64563,"marketCap":119524184},{"date":"2021-08-06","current":-8.290388,"twenty":-100.840692,"median":-22.020758,"eighty":-13.355558,"marketCap":80185717},{"date":"2021-08-13","current":-5.99167,"twenty":-100.840692,"median":-21.65648,"eighty":-13.337149,"marketCap":58684815},{"date":"2021-08-20","current":-5.242711,"twenty":-100.840692,"median":-21.054911,"eighty":-13.23074,"marketCap":51349213},{"date":"2021-08-27","current":-7.670371,"twenty":-100.840692,"median":-20.611957,"eighty":-13.105921,"marketCap":75126681},{"date":"2021-09-03","current":-8.393504,"twenty":-100.840692,"median":-20.536178,"eighty":-12.981103,"marketCap":82209331},{"date":"2021-09-10","current":-8.290199,"twenty":-100.840692,"median":-20.327641,"eighty":-12.731467,"marketCap":81197524},{"date":"2021-09-17","current":-7.386283,"twenty":-100.840692,"median":-20.25282,"eighty":-12.48183,"marketCap":72344211},{"date":"2021-09-24","current":-6.404889,"twenty":-100.840692,"median":-20.249018,"eighty":-12.48183,"marketCap":62732043},{"date":"2021-10-01","current":-5.862539,"twenty":-100.840692,"median":-20.143991,"eighty":-12.48183,"marketCap":57420056},{"date":"2021-10-08","current":-5.578452,"twenty":-96.807064,"median":-20.052297,"eighty":-12.48183,"marketCap":54637586},{"date":"2021-10-15","current":-6.998891,"twenty":-95.798657,"median":-20.052297,"eighty":-12.48183,"marketCap":68549935},{"date":"2021-10-22","current":-6.379063,"twenty":-95.798657,"median":-20.02901,"eighty":-12.357012,"marketCap":62479092},{"date":"2021-10-29","current":-6.885086,"twenty":-95.798657,"median":-20.005723,"eighty":-12.332048,"marketCap":67435282},{"date":"2021-11-05","current":-10.164989,"twenty":-93.770452,"median":-19.95676,"eighty":-12.112235,"marketCap":99559965},{"date":"2021-11-12","current":-8.999403,"twenty":-93.263401,"median":-19.851774,"eighty":-11.72383,"marketCap":88143755},{"date":"2021-11-19","current":-9.556177,"twenty":-93.263401,"median":-19.851774,"eighty":-11.230993,"marketCap":93218994},{"date":"2021-11-26","current":-9.294762,"twenty":-93.263401,"median":-19.851774,"eighty":-11.139591,"marketCap":90668931},{"date":"2021-12-03","current":-8.510516,"twenty":-93.263401,"median":-19.450728,"eighty":-11.097077,"marketCap":83018740},{"date":"2021-12-10","current":-10.108053,"twenty":-90.465498,"median":-19.450728,"eighty":-11.097077,"marketCap":98602462},{"date":"2021-12-17","current":-10.398515,"twenty":-88.60023,"median":-19.450728,"eighty":-11.097077,"marketCap":101435866},{"date":"2021-12-23","current":-10.950391,"twenty":-88.60023,"median":-19.250205,"eighty":-11.042884,"marketCap":106819334},{"date":"2021-12-31","current":-9.846638,"twenty":-88.60023,"median":-18.803806,"eighty":-10.973777,"marketCap":96052398},{"date":"2022-01-07","current":-9.90473,"twenty":-88.60023,"median":-18.754997,"eighty":-10.850476,"marketCap":96619079},{"date":"2022-01-14","current":-9.556177,"twenty":-88.60023,"median":-18.687731,"eighty":-10.850476,"marketCap":93218994},{"date":"2022-01-21","current":-7.900547,"twenty":-88.60023,"median":-18.539338,"eighty":-10.850476,"marketCap":77068591},{"date":"2022-01-28","current":-7.174394,"twenty":-88.60023,"median":-18.52056,"eighty":-10.712213,"marketCap":69985081},{"date":"2022-02-04","current":-7.319625,"twenty":-88.60023,"median":-18.401426,"eighty":-10.554554,"marketCap":71401783},{"date":"2022-02-11","current":-7.668178,"twenty":-88.60023,"median":-18.286122,"eighty":-10.404324,"marketCap":74801868},{"date":"2022-02-18","current":-7.348671,"twenty":-88.60023,"median":-18.220695,"eighty":-10.343792,"marketCap":71685123},{"date":"2022-02-25","current":-7.116302,"twenty":-88.60023,"median":-18.188702,"eighty":-10.164989,"marketCap":69418400},{"date":"2022-03-04","current":-7.116302,"twenty":-88.60023,"median":-18.047067,"eighty":-9.98737,"marketCap":69418400},{"date":"2022-03-11","current":-6.622518,"twenty":-88.60023,"median":-18.047067,"eighty":-9.875684,"marketCap":64601613},{"date":"2022-03-18","current":-6.564425,"twenty":-88.60023,"median":-17.909889,"eighty":-9.788546,"marketCap":64034932},{"date":"2022-03-25","current":-7.029163,"twenty":-88.60023,"median":-17.850261,"eighty":-9.704796,"marketCap":68568379},{"date":"2022-04-01","current":-6.339112,"twenty":-88.60023,"median":-17.739319,"eighty":-9.704796,"marketCap":81386671},{"date":"2022-04-08","current":-6.31572,"twenty":-88.60023,"median":-17.732346,"eighty":-9.704796,"marketCap":81086351},{"date":"2022-04-14","current":-5.894672,"twenty":-88.60023,"median":-17.680293,"eighty":-9.60846,"marketCap":75680594},{"date":"2022-04-22","current":-5.754323,"twenty":-88.60023,"median":-17.646021,"eighty":-9.54452,"marketCap":73878675},{"date":"2022-04-29","current":-5.590582,"twenty":-88.60023,"median":-17.646021,"eighty":-9.360688,"marketCap":71776436},{"date":"2022-05-06","current":-5.766019,"twenty":-88.60023,"median":-17.646021,"eighty":-9.252091,"marketCap":74028835},{"date":"2022-05-13","current":-5.2631,"twenty":-88.60023,"median":-17.58281,"eighty":-9.119715,"marketCap":67571959},{"date":"2022-05-20","current":-3.799171,"twenty":-88.60023,"median":-17.545855,"eighty":-9.098246,"marketCap":67267162},{"date":"2022-05-27","current":-3.527801,"twenty":-88.60023,"median":-17.467267,"eighty":-9.097299,"marketCap":62462364},{"date":"2022-06-03","current":-3.744897,"twenty":-88.60023,"median":-17.373275,"eighty":-9.093511,"marketCap":66306202},{"date":"2022-06-10","current":-1.628216,"twenty":-88.60023,"median":-17.227608,"eighty":-8.989743,"marketCap":28828783},{"date":"2022-06-17","current":-1.764263,"twenty":-88.60023,"median":-17.146548,"eighty":-8.906096,"marketCap":31237588},{"date":"2022-06-24","current":-1.790857,"twenty":-88.60023,"median":-17.057037,"eighty":-8.85907,"marketCap":31708458},{"date":"2022-07-01","current":-1.82722,"twenty":-88.60023,"median":-17.057037,"eighty":-8.794971,"marketCap":32352301},{"date":"2022-07-08","current":-1.881494,"twenty":-88.60023,"median":-16.871014,"eighty":-8.794971,"marketCap":33313261},{"date":"2022-07-15","current":-1.415282,"twenty":-88.60023,"median":-16.641799,"eighty":-8.791309,"marketCap":25058619},{"date":"2022-07-22","current":-1.4189,"twenty":-88.60023,"median":-16.368319,"eighty":-8.790393,"marketCap":25122683},{"date":"2022-07-29","current":-1.175934,"twenty":-88.60023,"median":-16.201757,"eighty":-8.70552,"marketCap":20820788},{"date":"2022-08-05","current":-1.14735,"twenty":-88.60023,"median":-16.10474,"eighty":-8.638835,"marketCap":20314682},{"date":"2022-08-12","current":-1.212116,"twenty":-88.60023,"median":-15.910707,"eighty":-8.55118,"marketCap":21461427},{"date":"2022-08-19","current":-1.600085,"twenty":-88.60023,"median":-15.82702,"eighty":-8.491696,"marketCap":28150574},{"date":"2022-08-26","current":-1.546748,"twenty":-88.60023,"median":-15.82702,"eighty":-8.487276,"marketCap":27212221},{"date":"2022-09-02","current":-1.875961,"twenty":-88.60023,"median":-15.82702,"eighty":-8.487276,"marketCap":33004121},{"date":"2022-09-09","current":-2.023095,"twenty":-88.60023,"median":-15.82702,"eighty":-8.340059,"marketCap":35592680},{"date":"2022-09-16","current":-1.3426,"twenty":-88.60023,"median":-15.800641,"eighty":-8.303464,"marketCap":23620596},{"date":"2022-09-23","current":-1.680089,"twenty":-88.60023,"median":-15.762085,"eighty":-8.21272,"marketCap":29558103},{"date":"2022-09-30","current":-1.618476,"twenty":-88.60023,"median":-15.716674,"eighty":-8.036784,"marketCap":28474144},{"date":"2022-10-07","current":-1.626753,"twenty":-88.60023,"median":-15.610527,"eighty":-7.747849,"marketCap":28619750},{"date":"2022-10-14","current":-1.287424,"twenty":-88.60023,"median":-15.563236,"eighty":-7.670371,"marketCap":22649887},{"date":"2022-10-21","current":-1.324208,"twenty":-88.60023,"median":-15.563236,"eighty":-7.581872,"marketCap":23297027},{"date":"2022-10-28","current":-1.359888,"twenty":-88.60023,"median":-15.563236,"eighty":-7.479591,"marketCap":23924752},{"date":"2022-11-04","current":-1.348301,"twenty":-88.60023,"median":-15.563236,"eighty":-7.430234,"marketCap":23720903},{"date":"2022-11-11","current":-1.327151,"twenty":-88.60023,"median":-15.563236,"eighty":-7.386283,"marketCap":23348798},{"date":"2022-11-18","current":-1.231758,"twenty":-88.60023,"median":-15.563236,"eighty":-7.319625,"marketCap":24008880},{"date":"2022-11-25","current":-1.245038,"twenty":-88.60023,"median":-15.522641,"eighty":-7.302197,"marketCap":24267736},{"date":"2022-12-02","current":-1.269773,"twenty":-88.60023,"median":-15.497757,"eighty":-7.288183,"marketCap":24749855},{"date":"2022-12-09","current":-1.228438,"twenty":-88.60023,"median":-15.445794,"eighty":-7.272153,"marketCap":23944166},{"date":"2022-12-16","current":-1.162036,"twenty":-88.60023,"median":-15.329372,"eighty":-7.261532,"marketCap":22649887},{"date":"2022-12-23","current":-1.145435,"twenty":-88.60023,"median":-15.299453,"eighty":-7.226677,"marketCap":22326317},{"date":"2022-12-30","current":-1.037532,"twenty":-88.60023,"median":-15.199238,"eighty":-7.174394,"marketCap":20223113},{"date":"2023-01-06","current":-1.512141,"twenty":-88.133914,"median":-15.199238,"eighty":-7.100329,"marketCap":29473974},{"date":"2023-01-13","current":-1.435777,"twenty":-86.576754,"median":-15.134575,"eighty":-6.953369,"marketCap":27985521},{"date":"2023-01-20","current":-1.29484,"twenty":-85.538648,"median":-15.003998,"eighty":-6.821454,"marketCap":25238445},{"date":"2023-01-27","current":-1.261473,"twenty":-85.538648,"median":-14.852734,"eighty":-6.739858,"marketCap":24588070},{"date":"2023-02-03","current":-1.167182,"twenty":-85.538648,"median":-14.654339,"eighty":-6.646897,"marketCap":22750194},{"date":"2023-02-10","current":-1.245038,"twenty":-70.569383,"median":-14.475627,"eighty":-6.564425,"marketCap":24267736},{"date":"2023-02-17","current":-1.203539,"twenty":-70.569383,"median":-14.327911,"eighty":-6.471848,"marketCap":23458844},{"date":"2023-02-24","current":-1.161758,"twenty":-70.569383,"median":-14.296916,"eighty":-6.418638,"marketCap":22644477},{"date":"2023-03-03","current":-1.170116,"twenty":-70.569383,"median":-14.296916,"eighty":-6.368733,"marketCap":22807387},{"date":"2023-03-10","current":-0.98808,"twenty":-70.569383,"median":-14.296916,"eighty":-6.32741,"marketCap":19259209},{"date":"2023-03-17","current":-1.002957,"twenty":-70.569383,"median":-14.296916,"eighty":-6.222154,"marketCap":19549189},{"date":"2023-03-24","current":-1.019673,"twenty":-70.569383,"median":-14.118204,"eighty":-6.090777,"marketCap":19875009},{"date":"2023-03-31","current":-1.069821,"twenty":-70.569383,"median":-14.118204,"eighty":-5.965645,"marketCap":20852468},{"date":"2023-04-06","current":-1.043077,"twenty":-70.569383,"median":-14.066248,"eighty":-5.910288,"marketCap":20331189},{"date":"2023-04-14","current":-1.321345,"twenty":-64.954263,"median":-14.066248,"eighty":-5.744966,"marketCap":21700767},{"date":"2023-04-21","current":-1.310948,"twenty":-60.422571,"median":-13.83181,"eighty":-5.658826,"marketCap":21530015},{"date":"2023-04-28","current":-1.398249,"twenty":-47.962314,"median":-13.730013,"eighty":-5.59802,"marketCap":22963775},{"date":"2023-05-05","current":-1.498124,"twenty":-47.962314,"median":-13.705049,"eighty":-5.49939,"marketCap":24604044},{"date":"2023-05-12","current":-1.558049,"twenty":-47.962314,"median":-13.64563,"eighty":-5.24151,"marketCap":25588206},{"date":"2023-05-19","current":-1.963531,"twenty":-47.962314,"median":-13.355558,"eighty":-3.791935,"marketCap":24056194},{"date":"2023-05-26","current":-1.809834,"twenty":-47.962314,"median":-13.299333,"eighty":-3.683387,"marketCap":22173165},{"date":"2023-06-02","current":-1.797516,"twenty":-46.033619,"median":-13.23074,"eighty":-3.614639,"marketCap":22022260},{"date":"2023-06-09","current":-1.684251,"twenty":-43.485789,"median":-12.981103,"eighty":-3.299851,"marketCap":20634592},{"date":"2023-06-16","current":-1.609276,"twenty":-39.895803,"median":-12.731467,"eighty":-2.015739,"marketCap":19716041},{"date":"2023-06-23","current":-1.446742,"twenty":-38.369814,"median":-12.48183,"eighty":-1.965287,"marketCap":17724753},{"date":"2023-06-30","current":-1.344455,"twenty":-36.826895,"median":-12.48183,"eighty":-1.921295,"marketCap":16471587},{"date":"2023-07-07","current":-1.241901,"twenty":-36.397248,"median":-12.48183,"eighty":-1.877068,"marketCap":15215141},{"date":"2023-07-14","current":-1.204949,"twenty":-33.757987,"median":-12.48183,"eighty":-1.845821,"marketCap":14762426},{"date":"2023-07-21","current":-1.017513,"twenty":-33.635231,"median":-12.357585,"eighty":-1.824236,"marketCap":12466049},{"date":"2023-07-28","current":-0.905985,"twenty":-32.837315,"median":-12.357012,"eighty":-1.794379,"marketCap":11099674},{"date":"2023-08-04","current":-0.900255,"twenty":-31.425617,"median":-11.857738,"eighty":-1.773608,"marketCap":11029470},{"date":"2023-08-11","current":-0.63419,"twenty":-30.638859,"median":-11.386083,"eighty":-1.73785,"marketCap":7769771},{"date":"2023-08-18","current":-0.55807,"twenty":-30.103498,"median":-11.220378,"eighty":-1.68709,"marketCap":7062935},{"date":"2023-08-25","current":-0.523965,"twenty":-29.033151,"median":-11.097077,"eighty":-1.675707,"marketCap":6631311},{"date":"2023-09-01","current":-0.420938,"twenty":-28.224507,"median":-11.097077,"eighty":-1.659207,"marketCap":5327390},{"date":"2023-09-08","current":-0.350246,"twenty":-27.178685,"median":-11.097077,"eighty":-1.647519,"marketCap":4432713},{"date":"2023-09-15","current":-0.343819,"twenty":-25.922457,"median":-10.973777,"eighty":-1.629248,"marketCap":4351379},{"date":"2023-09-22","current":-0.313422,"twenty":-25.608909,"median":-10.850476,"eighty":-1.618329,"marketCap":3966668},{"date":"2023-09-29","current":-0.321326,"twenty":-23.64226,"median":-10.850476,"eighty":-1.601441,"marketCap":4066710},{"date":"2023-10-06","current":-0.289162,"twenty":-22.775869,"median":-10.688976,"eighty":-1.580196,"marketCap":3659632},{"date":"2023-10-13","current":-0.282767,"twenty":-22.573417,"median":-10.456607,"eighty":-1.555984,"marketCap":3578704},{"date":"2023-10-20","current":-0.29562,"twenty":-21.87715,"median":-10.357272,"eighty":-1.530122,"marketCap":3741373},{"date":"2023-10-27","current":-0.411298,"twenty":-20.708929,"median":-10.28233,"eighty":-1.525237,"marketCap":5205388},{"date":"2023-11-03","current":-0.385592,"twenty":-20.392025,"median":-10.008413,"eighty":-1.495062,"marketCap":4880052},{"date":"2023-11-10","current":-0.347032,"twenty":-20.25282,"median":-9.861161,"eighty":-1.453706,"marketCap":4392046},{"date":"2023-11-17","current":-0.527039,"twenty":-20.061981,"median":-9.742695,"eighty":-1.436505,"marketCap":6466068},{"date":"2023-11-24","current":-1.186185,"twenty":-20.052297,"median":-9.704796,"eighty":-1.418894,"marketCap":14552898},{"date":"2023-12-01","current":-0.739897,"twenty":-20.005723,"median":-9.704796,"eighty":-1.398059,"marketCap":9077550},{"date":"2023-12-08","current":-0.734025,"twenty":-19.855784,"median":-9.614269,"eighty":-1.379383,"marketCap":9005506},{"date":"2023-12-15","current":-0.757514,"twenty":-19.851774,"median":-9.529855,"eighty":-1.357844,"marketCap":9293682},{"date":"2023-12-22","current":-0.645942,"twenty":-19.450728,"median":-9.294762,"eighty":-1.3426,"marketCap":7924845},{"date":"2023-12-29","current":-0.734025,"twenty":-19.297293,"median":-9.178577,"eighty":-1.336307,"marketCap":9005506},{"date":"2024-01-05","current":-0.88681,"twenty":-18.799586,"median":-9.116636,"eighty":-1.327539,"marketCap":10879973},{"date":"2024-01-12","current":-0.924547,"twenty":-18.612428,"median":-9.098246,"eighty":-1.320866,"marketCap":11342950},{"date":"2024-01-19","current":-0.793298,"twenty":-18.4748,"median":-9.093511,"eighty":-1.311971,"marketCap":9732698},{"date":"2024-01-26","current":-0.812646,"twenty":-18.270731,"median":-8.999403,"eighty":-1.29484,"marketCap":9970081},{"date":"2024-02-02","current":-0.973886,"twenty":-18.114699,"median":-8.888116,"eighty":-1.287424,"marketCap":11948272},{"date":"2024-02-09","current":-0.838445,"twenty":-18.019487,"median":-8.794971,"eighty":-1.269673,"marketCap":10286591},{"date":"2024-02-16","current":-0.825545,"twenty":-17.817247,"median":-8.794971,"eighty":-1.256593,"marketCap":10128336},{"date":"2024-02-23","current":-0.780398,"twenty":-17.732346,"median":-8.790393,"eighty":-1.250053,"marketCap":9574443},{"date":"2024-03-01","current":-0.780398,"twenty":-17.646021,"median":-8.785645,"eighty":-1.245038,"marketCap":9574443},{"date":"2024-03-08","current":-0.806197,"twenty":-17.646021,"median":-8.666669,"eighty":-1.242787,"marketCap":9890953},{"date":"2024-03-15","current":-1.202078,"twenty":-17.560637,"median":-8.610667,"eighty":-1.232053,"marketCap":12640641},{"date":"2024-03-22","current":-1.061836,"twenty":-17.368294,"median":-8.491696,"eighty":-1.227587,"marketCap":11165900},{"date":"2024-03-28","current":-1.202078,"twenty":-17.227608,"median":-8.487276,"eighty":-1.21683,"marketCap":12640641},{"date":"2024-04-05","current":-1.282217,"twenty":-17.050112,"median":-8.393504,"eighty":-1.215841,"marketCap":13483351},{"date":"2024-04-12","current":-1.151992,"twenty":-16.459254,"median":-8.335718,"eighty":-1.212048,"marketCap":12113948},{"date":"2024-04-19","current":-1.051818,"twenty":-16.10474,"median":-8.21272,"eighty":-1.209834,"marketCap":11060561},{"date":"2024-04-26","current":-1.592754,"twenty":-15.910707,"median":-7.968666,"eighty":-1.204842,"marketCap":16748850},{"date":"2024-05-03","current":-1.151992,"twenty":-15.82702,"median":-7.731497,"eighty":-1.203538,"marketCap":12113948},{"date":"2024-05-10","current":-1.101905,"twenty":-15.82702,"median":-7.634408,"eighty":-1.200338,"marketCap":11587254},{"date":"2024-05-17","current":-1.061836,"twenty":-15.734838,"median":-7.48459,"eighty":-1.18456,"marketCap":11165900},{"date":"2024-05-24","current":-0.858149,"twenty":-15.582152,"median":-7.430234,"eighty":-1.178636,"marketCap":10834083},{"date":"2024-05-31","current":-0.715889,"twenty":-15.563236,"median":-7.382,"eighty":-1.173177,"marketCap":9038058},{"date":"2024-06-07","current":-0.658318,"twenty":-15.563236,"median":-7.319625,"eighty":-1.165754,"marketCap":8311221},{"date":"2024-06-14","current":-0.711685,"twenty":-15.563236,"median":-7.290579,"eighty":-1.161858,"marketCap":8984974},{"date":"2024-06-21","current":-0.630227,"twenty":-15.512687,"median":-7.276703,"eighty":-1.151992,"marketCap":7956573},{"date":"2024-06-28","current":-0.631856,"twenty":-15.351334,"median":-7.261532,"eighty":-1.146431,"marketCap":7977141},{"date":"2024-07-05","current":-0.62594,"twenty":-15.258759,"median":-7.232486,"eighty":-1.131572,"marketCap":7902447},{"date":"2024-07-12","current":-0.703024,"twenty":-15.199238,"median":-7.174394,"eighty":-1.12194,"marketCap":8875638},{"date":"2024-07-15","current":-0.678244,"twenty":-15.199238,"median":-7.116302,"eighty":-1.119798,"marketCap":8562788},{"date":"2024-08-02","current":-0.716281,"twenty":-14.887513,"median":-6.941989,"eighty":-1.109939,"marketCap":9043003},{"date":"2024-08-09","current":-0.651797,"twenty":-14.669052,"median":-6.792928,"eighty":-1.091888,"marketCap":8228892},{"date":"2024-08-16","current":-0.751707,"twenty":-14.498482,"median":-6.738702,"eighty":-1.08187,"marketCap":8549966},{"date":"2024-08-23","current":-0.748193,"twenty":-14.327911,"median":-6.622518,"eighty":-1.078179,"marketCap":8510005},{"date":"2024-08-30","current":-0.721532,"twenty":-14.296916,"median":-6.562136,"eighty":-1.072328,"marketCap":8206761},{"date":"2024-09-06","current":-0.68602,"twenty":-14.296916,"median":-6.469219,"eighty":-1.069821,"marketCap":7802835},{"date":"2024-09-13","current":-0.727328,"twenty":-14.296916,"median":-6.411345,"eighty":-1.061836,"marketCap":8272684},{"date":"2024-09-20","current":-0.696727,"twenty":-14.296916,"median":-6.353237,"eighty":-1.054133,"marketCap":7924624},{"date":"2024-09-27","current":-0.695504,"twenty":-14.296916,"median":-6.321565,"eighty":-1.044289,"marketCap":7910709},{"date":"2024-10-04","current":-0.671793,"twenty":-14.118204,"median":-6.222154,"eighty":-1.036389,"marketCap":7641025},{"date":"2024-10-11","current":-0.50013,"twenty":-14.066248,"median":-6.067323,"eighty":-1.01984,"marketCap":5688519},{"date":"2024-10-18","current":-0.576109,"twenty":-14.066248,"median":-5.964847,"eighty":-1.014835,"marketCap":6552704},{"date":"2024-10-25","current":-0.757678,"twenty":-13.83181,"median":-5.814279,"eighty":-0.991815,"marketCap":8617878},{"date":"2024-10-31","current":-0.758731,"twenty":-13.730013,"median":-5.719235,"eighty":-0.980335,"marketCap":8629864},{"date":"2024-11-08","current":-0.571578,"twenty":-13.730013,"median":-5.630104,"eighty":-0.95093,"marketCap":6501164},{"date":"2024-11-15","current":-0.58064,"twenty":-13.64563,"median":-5.578452,"eighty":-0.920835,"marketCap":6604243},{"date":"2024-11-22","current":-0.799583,"twenty":-13.418762,"median":-5.497016,"eighty":-0.900947,"marketCap":6591059},{"date":"2024-11-29","current":-0.787271,"twenty":-13.355558,"median":-5.239709,"eighty":-0.895748,"marketCap":6489564},{"date":"2024-12-06","current":-0.794995,"twenty":-13.233835,"median":-3.78108,"eighty":-0.88234,"marketCap":6553235},{"date":"2024-12-13","current":-0.764989,"twenty":-13.105921,"median":-3.672532,"eighty":-0.851444,"marketCap":6305897},{"date":"2024-12-20","current":-0.769,"twenty":-12.89,"median":-3.527801,"eighty":-0.838445,"marketCap":6338957},{"date":"2024-12-27","current":-0.830348,"twenty":-12.631501,"median":-3.093611,"eighty":-0.825442,"marketCap":6844653},{"date":"2025-01-03","current":-0.952598,"twenty":-12.48183,"median":-2.023095,"eighty":-0.825442,"marketCap":7852372},{"date":"2025-01-10","current":-0.793212,"twenty":-12.48183,"median":-1.965726,"eighty":-0.824584,"marketCap":6538542},{"date":"2025-01-17","current":-0.818613,"twenty":-12.48183,"median":-1.915211,"eighty":-0.816226,"marketCap":6747922},{"date":"2025-01-24","current":-0.79247,"twenty":-12.48183,"median":-1.86954,"eighty":-0.811335,"marketCap":6532419},{"date":"2025-01-31","current":-0.772417,"twenty":-12.48183,"median":-1.845312,"eighty":-0.806197,"marketCap":6367119},{"date":"2025-02-07","current":-0.680321,"twenty":-12.48183,"median":-1.822285,"eighty":-0.800781,"marketCap":5607963},{"date":"2025-02-14","current":-0.62239,"twenty":-12.48183,"median":-1.794164,"eighty":-0.798943,"marketCap":5130429},{"date":"2025-02-21","current":-0.868969,"twenty":-12.48183,"median":-1.774601,"eighty":-0.794876,"marketCap":7163009},{"date":"2025-02-28","current":-1.185362,"twenty":-12.48183,"median":-1.738663,"eighty":-0.794876,"marketCap":9771079},{"date":"2025-03-07","current":-0.94517,"twenty":-12.48183,"median":-1.686929,"eighty":-0.794817,"marketCap":7791150},{"date":"2025-03-14","current":-1.021967,"twenty":-12.48183,"median":-1.674611,"eighty":-0.794817,"marketCap":8424189},{"date":"2025-03-21","current":-0.987802,"twenty":-12.48183,"median":-1.658971,"eighty":-0.794817,"marketCap":8142566},{"date":"2025-03-28","current":-1.186848,"twenty":-12.48183,"median":-1.64007,"eighty":-0.794817,"marketCap":9783324},{"date":"2025-04-04","current":-1.358413,"twenty":-12.48183,"median":-1.633375,"eighty":-0.794817,"marketCap":11197559},{"date":"2025-04-11","current":-1.559687,"twenty":-12.48183,"median":-1.622615,"eighty":-0.794876,"marketCap":12856684},{"date":"2025-04-17","current":-2.422481,"twenty":-12.48183,"median":-1.616463,"eighty":-0.794876,"marketCap":11877127}],"updateTime":1745128349975}}}